$1.58
+0.15
(+10.49%)▲
9.49%
Downside
Day's Volatility :12.54%
Upside
3.36%
18.35%
Downside
52 Weeks Volatility :92.77%
Upside
91.15%
Period | Dermata Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -52.12% | 0.0% |
6 Months | -74.62% | 0.0% |
1 Year | -91.0% | 0.0% |
3 Years | -99.88% | -22.3% |
Market Capitalization | 2.1M |
Book Value | $4.79 |
Earnings Per Share (EPS) | -18.73 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -90.68% |
Return On Equity TTM | -173.01% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -7.9M |
Diluted Eps TTM | -18.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -15.24 |
EPS Estimate Next Year | -3.87 |
EPS Estimate Current Quarter | -3.79 |
EPS Estimate Next Quarter | -3.73 |
What analysts predicted
Upside of 279.75%
Sell
Neutral
Buy
Dermata Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dermata Therapeutics Inc | -32.19% | -74.62% | -91.0% | -99.88% | -99.87% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dermata Therapeutics Inc | NA | NA | NA | -15.24 | -1.73 | -0.91 | NA | 4.79 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dermata Therapeutics Inc | Buy | $2.1M | -99.87% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Dermata Therapeutics Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 128.1%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 169.1%
Armistice Capital, LLC
Acadian Asset Management LLC
Geode Capital Management, LLC
dermata therapeutics, llc is a research company based out of 12340 el camino real, san diego, california, united states.
Organization | Dermata Therapeutics Inc |
Employees | 8 |
CEO | Mr. Gerald T. Proehl |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$1.58
+10.49%
Keyarch Acquisition Corp
$1.58
+10.49%
Connexa Sports Technologies Inc
$1.58
+10.49%
Us Value Etf
$1.58
+10.49%
First Wave Biopharma Inc
$1.58
+10.49%
Global X Msci Next Emerging
$1.58
+10.49%
Fat Projects Acquisition Corp
$1.58
+10.49%
Capital Link Global Fintech
$1.58
+10.49%
Applied Uv Inc
$1.58
+10.49%